|
Mar 25
|
5 Large Drug Stocks to Watch as Industry Recovers
|
|
Mar 25
|
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
|
|
Mar 24
|
Tempero secures $70m to advance addiction treatment candidate
|
|
Mar 24
|
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
|
|
Mar 24
|
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
|
|
Mar 22
|
Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli
|
|
Mar 21
|
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
|
|
Mar 21
|
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
|
|
Mar 21
|
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals
|
|
Mar 21
|
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
|
|
Mar 21
|
AstraZeneca deepens China investment; Editas loses CFO to Dyne
|
|
Mar 20
|
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
|
|
Mar 20
|
Novartis Reports Updated Positive Data From Phase III SMA Program
|
|
Mar 20
|
Novartis builds case for new SMA gene therapy
|
|
Mar 20
|
Novartis reports Phase III efficacy and safety outcomes of SMA treatment
|
|
Mar 20
|
Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
|
|
Jan 31
|
Novartis Pares Gains As Its Bread-And-Butter Drug Faces Looming Competition
|
|
Jan 31
|
Novartis Ag (NVS) Q4 2024 Earnings Call Transcript
|
|
Jan 31
|
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Jan 31
|
Health Care Roundup: Market Talk
|